Biopharmaceutical company Scancell Holdings plc (AIM: SCLP), a developer of novel oncology immunotherapies, revealed on Wednesday that it has granted a major international biotechnology company exclusivity to evaluate its investigational anti-glycan monoclonal antibody.
This antibody, part of Scancell's GlyMab platform, will be assessed for the development of novel therapeutic products. The agreement includes a USD1m exclusivity payment due within 30 days and lasts for seven months.
Scancell's anti-glycan monoclonal antibody is one of five developed using its proprietary GlyMab platform, which targets sugar motifs on cancer cells rather than proteins. This innovative approach allows the identification and development of multiple monoclonal antibodies against glycan targets, with a robust portfolio of patents supporting the technology.
The company is advancing a pipeline of differentiated anti-cancer monoclonal antibodies, including GlyMab and AvidiMab. The company leverages its proprietary research on the human adaptive immune system to create novel therapies for cancer and infectious diseases, utilising four technology platforms: Moditope and ImmunoBody for vaccines, along with GlyMab and AvidiMab for antibodies.
myTomorrows names new director
GSK's Arexvy receives positive CHMP opinion for at-risk adults aged 50-59
Latigo Biotherapeutics names new chief executive officer
Valneva receives CEPI funding to boost access to world's first chikungunya vaccine
Bavarian Nordic's chikungunya vaccine receives validation from EMA for accelerated review
GSK secures global rights to CureVac's mRNA vaccines in new licensing deal
INOVIO names new chief commercial officer
Dynavax Technologies commences dosing in Z-1018 phase 1/2 clinical trial
Bavarian Nordic files for chikungunya vaccine approval in Europe
Valneva's chikungunya vaccine IXCHIQ approved by Health Canada
Philippine lawmakers call for probe into secret US propaganda operation
Gavi seeking funding to immunise poorest children
Sanofi partners with Biovac to manufacture polio vaccines in Africa